Bogart Wealth LLC’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Bogart Wealth LLC’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2	Closed	-$2	–	1541
2025 Q2	$2	Hold	2	–	–	﹤0.01%	1450
2025 Q1	$3	Hold	2	–	–	﹤0.01%	1402
2024 Q4	$5	Hold	2	–	–	﹤0.01%	1339
2024 Q3	$8	Buy	+2	New	+$9	﹤0.01%	1124

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Bogart Wealth LLC's BCLI Position: Q3 2025 in Review

Bogart Wealth LLC sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 2 shares — an estimated $2 sold.

Bogart Wealth LLC first reported a position in BCLI in Q3 2024 and held it in 4 quarters. The position peaked at $8 in Q3 2024. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

Bogart Wealth LLC reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
Bogart Wealth LLC sold 2 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $2.
Bogart Wealth LLC first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2024 and held it in 4 quarters.
Bogart Wealth LLC's BRAINSTORM CELL THERAPUTC position peaked at $8 in Q3 2024.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Bogart Wealth LLC's 13F filing for Q3 2025, filed 27 Oct 2025.